

**Texas Prior Authorization Program
Clinical Criteria**

Drug/Drug Class**Phosphate Binders****Clinical Edit Information Included in this Document**

- **Drugs requiring prior authorization:** the list of drugs requiring prior authorization for this clinical criteria
- **Prior authorization criteria logic:** a description of how the prior authorization request will be evaluated against the clinical criteria rules
- **Logic diagram:** a visual depiction of the clinical criteria logic
- **Supporting tables:** a collection of information associated with the steps within the criteria (diagnosis codes, procedure codes, and therapy codes); provided when applicable
- **References:** clinical publications and sources relevant to this clinical criteria

Note: Click the hyperlink to navigate directly to that section.

Revision Notes

Annual review by staff

Added GCNs for Auryxia, calcium acetate, Phoslyra and Velphoro to 'Drugs Requiring PA', page 2

Updated references, page 6



Phosphate Binders

Drugs Requiring Prior Authorization

Drugs Requiring Prior Authorization	
Label Name	GCN
AURYXIA 210 MG TABLET	37075
CALCIUM ACETATE 667 MG CAPSULE	13675
CALCIUM ACETATE 667 MG TABLET	75051
FOSRENOL 500 MG TABLET CHEW	23813
FOSRENOL 750 MG POWDER PACKET	32453
FOSRENOL 750 MG TABLET CHEW	26116
FOSRENOL 1,000 MG POWDER PACKET	32454
FOSRENOL 1,000 MG TABLET CHEW	26115
LANTHANUM CARB 500 MG TAB CHEW	23813
LANTHANUM CARB 750 MG TAB CHEW	26116
LANTHANUM CARB 1,000 MG TB CHW	26115
PHOSLYRA 667 MG/5 ML SOLUTION	29943
VELPHORO 500 MG CHEWABLE TAB	36003



Phosphate Binders


Clinical Criteria Logic

1. Is the client \geq 18 years of age?
 - ☐ Yes (Approve – 365 days)
 - ☐ No (Deny)



Phosphate Binders

Clinical Criteria Logic Diagram





Phosphate Binders

Clinical Criteria Supporting Tables

Not applicable



Phosphate Binders

Clinical Criteria References

1. Clinical Pharmacology [online database]. Tampa, FL: Elsevier/Gold Standard, Inc.; 2016. Available at www.clinicalpharmacology.com. Accessed on April 2, 2018.
2. Micromedex [online database]. Available at www.micromedexsolutions.com. Accessed on April 2, 2018.
3. Fosrenol Prescribing Information. Lexington, MA, Shire US Inc. February 2016.
4. Gonzalez-Campoy JM, St. Jeor ST, Castorino K, et al. Clinical practice guidelines for healthy eating for the prevention and treatment of metabolic and endocrine diseases in adults: cosponsored by the American Association of Clinical Endocrinologists/the American College of Endocrinology and the Obesity Society. *Endocr Pract*. 2013 Sep-Oct;19(Suppl 3):1-82.
5. Auryxia Prescribing Information. Boston, MA. Keryx Biopharmaceuticals, Inc. November 2017.
6. Phoslyra Prescribing Information. Waltham, MA. Fresenius Medical Care North America. December 2017.
7. Velphoro Prescribing Information. Waltham, MA. Fresenius Medical Care North America. September 2017.

Publication History

The Publication History records the publication iterations and revisions to this document. Notes for the *most current revision* are also provided in the **Revision Notes** on the first page of this document.

Publication Date	Notes
01/31/2011	Initial publication and posting to website
10/13/2011	Added a new section to specify the drugs requiring prior authorization
01/15/2016	Added GCNs for the powder packets
04/02/2018	Annual review by staff Added GCNs for Auryxia, calcium acetate, Phoslyra and Velphoro to 'Drugs Requiring PA', page 2 Updated references, page 6